Woodline Partners’s Tango Therapeutics TNGX Stock Holding History
Bought
Maintained
Sold
Other funds holding TNGX
RI
BCM
TCM
FCM
NI
TGI
SL
Woodline Partners's TNGX Position: Q1 2026 in Review
Woodline Partners reduced its Tango Therapeutics (TNGX) stake by 21% in Q1 2026, selling an estimated $28.8M and leaving 8,000,013 shares worth $167M. The position accounts for 0.63% of the portfolio, ranked #17.
Woodline Partners first reported a position in TNGX in Q3 2020 and has held it in 20 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.
- Woodline Partners held 8,000,013 shares of Tango Therapeutics worth $167M as of Q1 2026.
- Woodline Partners sold 2,072,212 Tango Therapeutics shares in Q1 2026, an estimated $28.8M.
- Tango Therapeutics made up 0.63% of Woodline Partners's portfolio in Q1 2026, its #17 holding.
- Woodline Partners first reported a position in Tango Therapeutics in Q3 2020 and has held it in 20 quarters since.
- 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.
Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.